https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-12-10 / Br. J. Cancer 2020 Jan;122(1):111-120
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-12-10 / Br. J. Cancer 2020 Jan;122(1):111-1202019-12-10 00:00:002019-12-10 00:00:00Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-12-05 / Cancer Immunol. Immunother. 2020 Jan;69(1):135-145
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-12-05 / Cancer Immunol. Immunother. 2020 Jan;69(1):135-1452019-12-05 00:00:002019-12-05 00:00:00Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-27 / Nat Commun 2019 11;10(1):5408
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-27 / Nat Commun 2019 11;10(1):54082019-11-27 00:00:002020-08-26 13:58:03Engineering dendritic cell vaccines to improve cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-26 / J Transl Med 2019 11;17(1):391
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-26 / J Transl Med 2019 11;17(1):3912019-11-26 00:00:002020-08-26 13:58:47A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-25 / J Immunol Res 2019;2019:9631515
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-25 / J Immunol Res 2019;2019:96315152019-11-25 00:00:002019-11-25 00:00:00Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-7552019-11-15 00:00:002019-11-15 00:00:00Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-14 / J Immunother Cancer 2019 Nov;7(1):3022019-11-14 00:00:002019-11-14 00:00:00Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-14 / Front Oncol 2019;9:1169
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-14 / Front Oncol 2019;9:11692019-11-14 00:00:002019-11-14 00:00:00Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Int J Cancer 2020 01;146(2):531-541
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Int J Cancer 2020 01;146(2):531-5412019-11-01 00:00:002020-12-14 17:16:09Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-11-01 / Front Oncol 2019;9:1012
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-11-01 / Front Oncol 2019;9:10122019-11-01 00:00:002021-05-12 07:14:18Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist
